Teva Pharmaceutical Industries (TEVA) Retained Earnings (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Retained Earnings for 18 consecutive years, with $28.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 0.9% year-over-year to $28.3 billion; the trailing twelve-month figure through Jun 2026 stood at $28.3 billion (up 0.9% YoY), and the FY2025 full-year result was $28.1 billion, up 1.33% from the prior year.
• Retained Earnings was little changed at $28.3 billion in Q2 2026 per TEVA's latest filing, from $28.2 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $28.3 billion in Q2 2026 and bottomed at -$14.1 billion in Q2 2023.
• Historically, Retained Earnings has averaged $16.6 billion across 5 years, with a median of $27.8 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Retained Earnings tumbled 147.83% in 2023, then jumped 310.67% in 2024.
• Over 5 years, Retained Earnings stood at $27.7 billion in 2022, then grew by 0.43% to $27.8 billion in 2023, then fell by 0.15% to $27.8 billion in 2024, then advanced by 1.33% to $28.1 billion in 2025, then grew by 0.44% to $28.3 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $28.3 billion, $28.2 billion, and $28.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.